. Author manuscript; available in PMC: 2014 Feb 1.

Published in final edited form as: Aliment Pharmacol Ther. 2012 Dec 13;37(4):10.1111/apt.12182. doi: 10.1111/apt.12182

Table 3.

Crude and multivariate adjusted^¶ estimates (odds ratios and 95% CI) of medication use and zoster in patients with IBD, overall and by CD or UC

		IBD Overall (n=13,129)		Crohns disease (n=6688)		Ulcerative Colitis (n=6381)
	Medication	Crude OR, 95% CI	Adjusted OR, 95% CI	Crude OR, 95% CI	Adjusted OR, 95% CI	Crude OR, 95% CI	Adjusted OR, 95% CI
Any use in prior 120 days
	5-ASA	1.20 (1.09-1.32)	1.08 (0.97-1.19)	1.27 (1.10-1.46)	1.09 (0.94-1.27)	1.14 (1.00-1.31)	1.07 (0.93-1.24)
	Biologic	2.57 (2.13-3.10)	1.81 (1.48-2.21)	2.37 (1.92-2.92)	1.72 (1.38-2.15)	3.85 (2.47-6.00)	2.36 (1.47-3.79)
	Thiopurine	2.28 (2.00-2.60)	1.85 (1.61-2.13)	2.31 (1.98-2.70)	1.93 (1.63-2.28)	2.20 (1.73-2.78)	1.68 (1.30-2.16)
	Corticosteroid	2.53 (2.22-2.87)	1.73 (1.51-1.99)	2.28 (1.91-2.72)	1.54 (1.27-1.86)	2.83 (2.34-3.43)	1.96 (1.60-2.40)

^{* **}

Biologic defined as infliximab, adalimumab, or certolizumab pegol, thiopurine defined as mercaptopurine or azathioprine 5-ASA defined as mesalamine, olsalazine, balsalazide, sulfasalazine,

^¶

adjusted for health care utilization, comorbidities, 5-ASA, biologic, thiopurine, corticosteroid use as appropriate (see methods)